# OnCo record impactmf (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/impactmf/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "impactmf", "NCT04576156" ;
  schema:name "IMpactMF"@en ;
  schema:alternateName "MYF3001"@en ;
  schema:description "IMpactMF is the first myelofibrosis trial designed to prove that a drug helps people live longer rather than just shrinking the spleen; it compares the telomerase blocker imetelstat with the best treatment doctors can otherwise offer after a JAK inhibitor has stopped working, and results are expected towards 2028."@en ;
  schema:url <https://onco.cc/trials/impactmf/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04576156> ;
  onco:status "active" ;
  onco:tag "soc-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/primary-myelofibrosis/>, <https://onco.cc/cancers/myeloproliferative-neoplasms/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/imetelstat/> ;
  onco:companies <https://onco.cc/companies/geron/> .